Lexagene Holdings (Lexagene Holdings) Total Inventories : $1.45 Mil (As of Nov. 2022)

View and export this data going back to 2017. Start your Free Trial

What is Lexagene Holdings Total Inventories?

Lexagene Holdings's total inventories for the quarter that ended in Nov. 2022 was $1.45 Mil. Lexagene Holdings's average total inventories from the quarter that ended in Aug. 2022 to the quarter that ended in Nov. 2022 was $1.47 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Lexagene Holdings's Net-Net Working Capital per share for the quarter that ended in Nov. 2022 was $-0.01.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Lexagene Holdings's Days Inventory for the three months ended in Nov. 2022 was 705.27.

Inventory Turnover measures how fast the company turns over its inventory within a year. Lexagene Holdings's Inventory Turnover for the quarter that ended in Nov. 2022 was 0.13.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Lexagene Holdings's Inventory-to-Revenue for the quarter that ended in Nov. 2022 was 34.15.

Lexagene Holdings Total Inventories Historical Data

The historical data trend for Lexagene Holdings's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lexagene Holdings Total Inventories Chart

Lexagene Holdings Annual Data

Trend

Mar13

Mar14

Mar15

Feb16

Feb17

Feb18

Feb19

Feb20

Feb21

Feb22

Total Inventories

Get a 7-Day Free Trial

1.07

1.40

Lexagene Holdings Quarterly Data
	Feb18	May18	Aug18	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22
Total Inventories	Get a 7-Day Free Trial															1.40	1.40	1.43	1.49	1.45

Lexagene Holdings Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Lexagene Holdings (OTCPK:LXXGQ) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Lexagene Holdings's Net-Net Working Capital Per Share for the quarter that ended in Nov. 2022 is

	Net-Net Working Capital Per Share (Q: Nov. 2022 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(0.464	+	0.75 * 0.052	+	0.5 * 1.445	-	2.217
-	0	-	0)	/	140.497
=	-0.01

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Lexagene Holdings's Days Inventory for the three months ended in Nov. 2022 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Nov. 2022 )	/	Cost of Goods Sold (Q: Nov. 2022 )	*	Days in Period
	=	1.4685	/	0.19	*	365 / 4
	=	705.27

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Lexagene Holdings's Inventory Turnover for the quarter that ended in Nov. 2022 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Nov. 2022 )	/	Average Total Inventories (Q: Nov. 2022 )
	=	0.19	/	1.4685
	=	0.13

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Lexagene Holdings's Inventory to Revenue for the quarter that ended in Nov. 2022 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Nov. 2022 )	/	Revenue (Q: Nov. 2022 )
	=	1.4685	/	0.043
	=	34.15

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Lexagene Holdings Total Inventories Related Terms

Thank you for viewing the detailed overview of Lexagene Holdings's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Lexagene Holdings (Lexagene Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lexagene Holdings Inc (OTCPK:LXXGQ) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

N/A

Address

500 Cummings Center, Suite 4550, Beverly, MA, USA, 01915

Website

https://www.lexagene.com

Lexagene Holdings Inc is a molecular diagnostics company that develops molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for on-site rapid testing in veterinary diagnostics, and for use in open-access markets such as food and water safety, clinical research, agricultural testing and biodefense. The MiQLab system delivers sensitivity, specificity, and breadth of detection and can return results in approximately two hours. The unique open-access feature is designed for custom testing so that end-users can load their own real-time PCR assays onto the instrument to target any genetic target of interest.